ARQT logo

Arcutis Biotherapeutics, Inc. Common Stock


ARQT: Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.


Show ARQT Financials

Consumer Interest
SEC Filings

Recently reported changes by institutional investors

Quarterly net insider trading by ARQT's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Laureth-4 containing topical formulations Aug. 22, 2023
  • Patent Title: Topical roflumilast formulation having antifungal properties Jul. 25, 2023
  • Patent Title: Compositions and methods for deep dermal drug delivery Apr. 18, 2023
  • Patent Title: Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents Dec. 27, 2022
  • Patent Title: Topical roflumilast formulation having improved delivery and plasma half life Sep. 28, 2021

Number of mentions of ARQT in WallStreetBets Daily Discussion


Recent insights relating to ARQT

CNBC Recommendations

Recent picks made for ARQT stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ARQT

Corporate Flights

Flights by private jets registered to ARQT